Keywords: eisai, challenges, nice, transparency, uk, subsidiary, japanese

Eisai challenges NICE on transparency

Article | 17 July 2006

Print This

The UK subsidiary of Japanese drug major Eisai, and maker of the Alzheimer's disease treatment Aricept (donepezil), has announced its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in